GENERAL COMMENTS
This is a clear and well written paper. It would benefit from a flow diagram explaining how papers were finally included for the review.
In terms of clarification I would welcome some clarity that the papers reporting TTR did all actually report this according to Rosendaal's equation. TTR is often claimed when in fact number of tests in range is the parameter being recorded.
Again, simply to imporve the paper I would like further comment on the 122 papers which were excluded as they did not report even 1 INR outcome measure. 
REVIEWER

GENERAL COMMENTS
This is a well done, well written paper, with a clear objective, adequate methods and a hard job done to review all needed litterature. The problem, to me, is that the objective of the paper is of very little relevance to clinical practice. Assessing the type and consistency of measures reported in studies evaluating vitamin K antagonists may certainly be of interest for researchers working in systematic reviews of this type of studies, or planning controlled trials involving VKAs, but has no implication at all for clinical practice, or the management of those patients. I think this paper is better suited to more specialized journals. 2. The authors never discuss what they call a "recommendation" for at least 2 parameters. The objective of the work is to describe the degree of standardisation of parameters used to describe VKA control measure in AF and VTE studies, not the number of parameters used. This criterion "at least 2 parameters" is clearly not relevant to answer to this main question, and could suggest a wrong answer! You may compute more than 10 parameters but none of them adequately or including the most common parameters used in the other studies… Is it a good point? A too large number of parameters is never useful to describe the anticoagulation level, and a bad one if the parameters are also endpoints of the study (due to the multiplicity of tests). So the context deserves to be explained. I would advice the authors to determine what is for us a good way for reporting quality of anticoagulation? At least TTR + 1 other? 3. The number of measures reported is for me not a good criterion to assess the degree of standardization between studies. However, some other parameters could be explored to describe the standardisation: when the frequency of INR was reported, was the measure adjusted to the length of follow-up? How was computed the TTR? Excluding or not the acute phase? In some studies, the first two weeks of VKA are excluded, in some other it is one month… These criteria suffer from a lack of standardization but it was not discussed in the paper. 4. To assess the impact of the work published by Fitzmaurice, I recommend starting your selection after his publication (2004) and not since his end of selection (2000) . To compare your results to the results published by Fitzmaurice, some data are needed to describe the previous review (e.g. the number os studies, AF and VTE, RCTs or observational…). 5. It could be of interest to study the subgroup of studies involving or not a new oral anticoagulant.
Page 2. Abstract:
The objective is clearer in the article focus (page3) than in the abstract. There is potential confusion for the reader between ≥ 1 control measure and ≥ 2 at this time of the reading.
VERSION 1 -AUTHOR RESPONSE
Reviewer D. Fitzmaurice comments: This is a clear and well written paper.
Thank you.
It would benefit from a flow diagram explaining how papers were finally included for the review.
We are including Figure 1 , a (PRISMA-style) flow diagram.
We have clarified in the methods text that for the purposes on this systematic review, linear interpolation (Rosendaal method) had to be used to say a study calculated TTR.
Again, simply to imporve the paper I would like further comment on the 122 papers which were excluded as they did not report even 1 INR outcome measure.
We have added text to the results to highlight that 112 papers did not report at least a single INR measure.
Reviewer C. Lafuente-Lafuente comments: This is a well done, well written paper, with a clear objective, adequate methods and a hard job done to review all needed litterature.
The problem, to me, is that the objective of the paper is of very little relevance to clinical practice. Assessing the type and consistency of measures reported in studies evaluating vitamin K antagonists may certainly be of interest for researchers working in systematic reviews of this type of studies, or planning controlled trials involving VKAs, but has no implication at all for clinical practice, or the management of those patients. I think this paper is better suited to more specialized journals.
We agree this paper is geared more towards aiding clinical trialists and meta-analysts in designing and presenting future research (although we do not see this as a limitation of our work). We have added text to the abstract, introduction and discussion to make this clear (and early on). We do; however, feel other end users (clinicans) may benefit from a better understanding of VKA control measure reporting in studies that guide their everyday practice. Finally, we choose to submit this manuscript to BMJ Open because of the journal's stated scope:
"We particularly hope that BMJ Open will attract work that deserves publication but does not quite meet the specific needs of the audiences of TheBMJ and the specialist journals from BMJ, which is why the journal will not judge papers on more subjective criteria of novelty or potential impact."
Otherwise, I find little comments or critics to do : tables 3, 4 and 5 could be shortened to show what is their main finding: the difference in the number of VKA control measures between various subgroups of studies ;
We believe there is valuable data in tables 3, 4 and 5 (more data is better in this case); however, if the editor wishes we could remove data/truncate these tables. Note, we make an effort to highlight the main/key findings in results section text.
and in discussion, page 8 -line 34, "desperate findings" should be corrected to "disparate findings"
Corrected.
Reviewer Laporte Comments:
The objective of the paper of E. Mearns et al. is to describe the degree of standardisation of VKA control measure reporting in AF and VTE studies since 2000, date of the previous review on the same topic. This paper is based on a tremendous work of literature search and analysis. I would like to make some comments, especially regarding the key messages of the paper.
Thank you for your in-depth review.
1. The paper is difficult to understand probably for a problem of wording: what do you mean by VKA control measure? For me, a VKA control measure is a single INR, not a parameter used to summarize the values of INR for a given patient, and that will be analysed as an endpoint. You question is related to the parameters used to summarize the level of anticoagulation. Please clarify.
We have added a definition early on in the introduction to clarify what we mean by a "VKA control measure". We hope this will improve clarity.
2. The authors never discuss what they call a "recommendation" for at least 2 parameters. The objective of the work is to describe the degree of standardisation of parameters used to describe VKA control measure in AF and VTE studies, not the number of parameters used. This criterion "at least 2 parameters" is clearly not relevant to answer to this main question, and could suggest a wrong answer! You may compute more than 10 parameters but none of them adequately or including the most common parameters used in the other studies… Is it a good point? A too large number of parameters is never useful to describe the anticoagulation level, and a bad one if the parameters are also endpoints of the study (due to the multiplicity of tests). So the context deserves to be explained. I would advice the authors to determine what is for us a good way for reporting quality of anticoagulation? At least TTR + 1 other?
Each measure of reporting VKA control has its strengths and weaknesses which we outline in the second and third to last paragraph of the discussion.
We added our recommendation of at least 2 measures of VKA control be reported, with one being TTR.
The above points are now discussed in the discussion section, including the strengths and weaknesses of the most commonly reported control measures and inclusion/exclusion of the INR measurements at treatment initiation and around temporary interruptions 4. To assess the impact of the work published by Fitzmaurice, I recommend starting your selection after his publication (2004) and not since his end of selection (2000) . To compare your results to the results published by Fitzmaurice, some data are needed to describe the previous review (e.g. the number os studies, AF and VTE, RCTs or observational…).
We have performed a subgroup analysis on studies published from 2000-2003 compared to 2004-current (see Table 5 ). We have added additional description regarding Fitzmaurice's work; however, because of its small size, we also suggest "that direct comparison between these systematic reviews should be made with caution."
5. It could be of interest to study the subgroup of studies involving or not a new oral anticoagulant.
We have added data to the results section text regarding the NOAC study subgroup. As the relative number of studies are small, we did not attempt to compare it to a not a NOAC study subgroup.
The wording was changed to eliminate potential confusion.
